[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053348":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":22,"locations":28,"responsibleParty":43,"collaborators":47,"id":51,"slug":21,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":21,"eligibilityCriteria":55,"healthyVolunteers":52,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":21,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":71,"overallStatus":30,"whyStopped":21,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Kisspeptin administration","EXPERIMENTAL","Single bolus of kisspeptin",[13],"Drug: Kisspeptin 112-121",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","Kisspeptin 112-121",[9],[20],"Metastin 45-54",null,[23],{"name":24,"role":25,"phone":26,"phoneExt":21,"email":27},"Study Coordinator","CONTACT","617-643-2308","MGHKisspeptinResearch@partners.org",[29],{"facility":5,"status":30,"city":31,"state":32,"zip":33,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"RECRUITING","Boston","Massachusetts","02114","United States",{"type":36,"coordinates":37},"Point",[38,39],-71.05977,42.35843,{"lat":39,"lon":38},[42],{"name":24,"role":25,"phone":26,"phoneExt":21,"email":27},{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"SPONSOR_INVESTIGATOR","Stephanie B. Seminara, MD","Chief, Reproductive Endocrine Unit; Professor of Medicine, Harvard Medical School; Director, MGH Harvard Center for Reproductive Medicine",[48],{"name":49,"class":50},"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","NIH","100053348",false,"NCT07224490","Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease","Inclusion Criteria\n\n* Female (ages 18-45 years) or Male (ages 18-60 years)\n* No current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and its method of administration\n* For women, negative serum hCG pregnancy test\n* For cases, diagnosis of post-covid-19 syndrome\n* For controls, history of prior covid infection but no diagnosis of post-covid-19 syndrome\n\nExclusion Criteria\n\n* Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in\u002Fcompletion of the protocol or the interpretation of results\n* Active use of illicit drugs (not including marijuana)\n* For women,\n* Pregnant\n* Trying to become pregnant during protocol participation\n* Breast feeding\n* Surgical or natural menopause","ALL","18 Years","60 Years",{"count":60,"type":61},40,"ESTIMATED","INTERVENTIONAL",[64],"PHASE1","The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin.",[67,68,69,70],"Reproductive Disorder","Neurodegeneration","SARS-CoV 2","Long COVID",[72,68,69,73,70],"Reproductive disorder","Kisspeptin","2026-07-09",{"date":76,"type":77},"2026-07-13","ACTUAL",{"date":79,"type":77},"2026-03-10",{"date":81,"type":61},"2030-05",{"name":45,"class":6},1]